Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826)
Hong Kong · Delayed Price · Currency is HKD 24.14
+0.28 (1.17%)
Mar 6, 2026, 4:08 PM HKT
HKG:6826 Revenue
In the year 2025, Shanghai Haohai Biological Technology had annual revenue of 2.47B CNY, down -7.71%. Shanghai Haohai Biological Technology had revenue of 573.93M in the quarter ending December 31, 2025, a decrease of -7.85%.
Revenue
2.47B CNY
Revenue Growth
-8.33%
P/S Ratio
3.62
Revenue / Employee
1.15M CNY
Employees
2,156
Market Cap
9.96B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.47B | -206.65M | -7.71% |
| Dec 31, 2024 | 2.68B | 44.76M | 1.70% |
| Dec 31, 2023 | 2.63B | 531.47M | 25.27% |
| Dec 31, 2022 | 2.10B | 353.32M | 20.19% |
| Dec 31, 2021 | 1.75B | 425.69M | 32.14% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CK Life Sciences Int'l., (Holdings) | 5.49B |
| Keymed Biosciences | 955.73M |
| Everest Medicines | 932.82M |
| HBM Holdings | 908.35M |
| Alphamab Oncology | 861.24M |
| Lepu Biopharma | 767.54M |
| Abbisko Cayman | 681.17M |
| CStone Pharmaceuticals | 221.89M |